by Alex Kadhim
In a phase 1 trail conducted by the Department of Rheumatology and Clinical Immunology at Charité University Medical Center Berlin, with collaborators at Leiden University Medical Center,...
by Alex Kadhim
Researchers at the the Department of Hematology and Hematopoietic Cell Transplantation, with correlative analyses contributed by the University of Washington and the Keck School of Medicine of...
by ASTCT Talks and Oncology On the Go
In a cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, an expert...
by Marco Ruiz, Marc J. Braunstein
As transplantation and cellular therapy expand to older patient populations, defining fitness has become increasingly complex. In this thought leadership article, Marco Ruiz, MD, MPH, MSc,...
by Clinical Cancer Research
The efficacy of chimeric antigen receptor (CAR) T-cell therapy targeting interleukin 13 receptor α2 (IL13Rα2) for patients with malignant gliomas has yet to be determined, but Phase I evidence...
by Transplantation and Cellular Therapy
A retrospective analysis suggests that cellular immunotherapy may offer a survival advantage over pharmacological immunosuppression in the setting of graft-versus-host disease (GVHD) following...